In many OECD countries, reimbursement policies, especially for drugs, are based on HTA. For instance, in Iceland and Ireland, HTA is solely used to help determine pharmaceutical coverage. The main lesson from the experiences of Australia, Canada and the United Kingdom is that HTA has provided useful evidence to inform reimbursement policies as well as improved patients’ access to cost-effective treatments (Lopert and Elshaug, 2013, Clement et al.,